Company intelligence / Profile preview

QUE Oncology

Melbourne, Victoria, Australiaqueoncology.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

QUE Oncology’s lead candidate, Q‑122, is an orally bioavailable small molecule currently in Phase 2 trials for the treatment of hot flashes in breast cancer survivors on endocrine therapy. The compound has demonstrated an excellent safety profile so far. The ongoing Phase 2 study spans clinical sites in the US, Australia, and New Zealand. Results were anticipated in 2020; however, no recent updates are available from the provided sources regarding trial completion or results.

Therapeutic areas: Women's HealthOncology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

Q-122

Partnerships

Brandon BioCatalyst

Beyond the preview

Go deeper on QUE Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QUE Oncology.

Explore the full profile